Robert W. Baird restated their buy rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a report issued on Tuesday. The firm currently has a $102.00 price target on the stock.

A number of other analysts have also recently commented on SRPT. Needham & Company LLC lifted their target price on Sarepta Therapeutics from $47.00 to $81.00 and gave the stock a buy rating in a research report on Wednesday, September 14th. Oppenheimer Holdings, Inc. reiterated an outperform rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, September 14th. SunTrust Banks, Inc. upgraded Sarepta Therapeutics from a reduce rating to a neutral rating in a research report on Wednesday, September 14th. Jefferies Group restated an underperform rating and issued a $7.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 15th. Finally, JMP Securities restated an underperform rating and issued a $10.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and an average price target of $60.06.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 36.73 on Tuesday. The stock’s market cap is $2.01 billion. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73. The firm’s 50-day moving average price is $32.17 and its 200-day moving average price is $33.99.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Thursday, October 27th. The company reported ($0.95) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.32) by $0.37. During the same period last year, the firm posted ($1.25) EPS. On average, analysts predict that Sarepta Therapeutics will post ($5.15) earnings per share for the current year.

WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of international trademark & copyright laws. The correct version of this story can be read at http://www.watchlistnews.com/sarepta-therapeutics-inc-srpt-earns-buy-rating-from-robert-w-baird/1059769.html.

In related news, insider Sandesh Mahatme sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, October 17th. The stock was sold at an average price of $50.08, for a total value of $1,502,400.00. Following the sale, the insider now owns 61,532 shares of the company’s stock, valued at approximately $3,081,522.56. The transaction was disclosed in a filing with the SEC, which is available through this link. 10.90% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. First Midwest Bank Trust Division raised its stake in Sarepta Therapeutics by 36.2% in the second quarter. First Midwest Bank Trust Division now owns 32,954 shares of the company’s stock worth $628,000 after buying an additional 8,754 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $4,712,000. Emerald Advisers Inc. PA acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $4,491,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter worth $211,000. Finally, Bank of New York Mellon Corp raised its position in shares of Sarepta Therapeutics by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 221,818 shares of the company’s stock worth $4,231,000 after buying an additional 2,282 shares in the last quarter. 76.99% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.